CD30 expression and survival in posttransplant lymphoproliferative disorders

References

• Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–562.
   PubMed Web of Science ®Google Scholar
• Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196–206.
   PubMed Web of Science ®Google Scholar
• Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011;11(2):336–347.
   PubMed Web of Science ®Google Scholar
• DeStefano CB, Desai SH, Shenoy AG, et al. Management of post-transplant lymphoproliferative disorders. Br J Haematol. 2018;182(3):330–343.
   PubMed Web of Science ®Google Scholar
• Kinch A, Baecklund E, Backlin C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 2014;53(5):669–679.
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123–1131.
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–1402.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Smith SM, Nabhan, C, et al. Brentuximab vedotin (BV) plus rituximab (R) as frontline therapy for patients (pts) with epstein barr virus (EBV)+ and/or CD30+ lymphoma: phase I results of an ongoing phase I–II study. Blood. 2014;124(21):3096–3096.
   Web of Science ®Google Scholar
• Hill BT, Tubbs RR, Smith MR. Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. Leuk Lymphoma. 2015;56(5):1552–1553.
   PubMed Web of Science ®Google Scholar
• Choi M, Fink S, Prasad V, et al. T Cell PTLD successfully treated with single-agent brentuximab vedotin first-line therapy. Transplantation. 2016;100(3):e8–e10.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Steurer M, Glodny B, et al. First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis. Liver Transpl. 2014;20(9):1145–1148.
   PubMed Web of Science ®Google Scholar
• Berger GK, McBride A, Lawson S, et al. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review. Crit Rev Oncol Hematol. 2017;109:42–50.
   PubMed Web of Science ®Google Scholar
• Mika T, Strate K, Ladigan S, et al. Refractory Epstein-Barr Virus (EBV)-related post-transplant lymphoproliferative disease: cure by combined brentuximab vedotin and allogeneic EBV-specific T-lymphocytes. Front Med (Lausanne)). 2019;6:295.
   PubMed Web of Science ®Google Scholar
• van der Weyden CA, Pileri SA, Feldman AL, et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603–e603.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–2724.
   PubMed Web of Science ®Google Scholar
• Vase MO, Maksten EF, Bendix K, et al. Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. Leuk Lymphoma. 2015;56(6):1677–1685.
   PubMed Web of Science ®Google Scholar
• Schober T, Framke T, Großhennig A, et al. CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target. Leuk Lymphoma. 2015;56(3):832–833.
   PubMed Web of Science ®Google Scholar
• Hartley C, Vaughan JW, Jarzembowski J, et al. CD30 expression in monomorphic posttransplant lymphoproliferative disorder, diffuse large B-cell lymphoma correlates with greater regulatory T-cell infiltration. Am J Clin Pathol. 2017;148(6):485–493.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Smith MR, Siddiqi T, et al. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017;58(7):1607–1616.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Berglund D, Kinch A, Edman E, et al. Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes. Transplantation. 2015;99(5):1036–1042.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: World Health Organization; 2017.
   Google Scholar
• Kampers J, Orjuela-Grimm M, Schober T, et al. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. Leuk Lymphoma. 2017;58(3):633–638.
   PubMed Web of Science ®Google Scholar
• Malysz J, Erdman P, Klapper J, et al. Clinical implications of CD30 expression in aggressive B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2016;16(8):429–433.
   PubMed Web of Science ®Google Scholar
• Koff JL, Li JX, Zhang X, et al. Impact of the posttransplant lymphoproliferative disorder subtype on survival. Cancer. 2018;124(11):2327–2336.
   PubMed Web of Science ®Google Scholar
• Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013;31(10):1302–1309.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma [Multicenter Study]. Haematologica. 2008;93(2):193–200.
   PubMed Web of Science ®Google Scholar
• Richendollar BG, Tsao RE, Elson P, et al. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk Lymphoma. 2009;50(12):2005–2012.
   PubMed Web of Science ®Google Scholar